Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy
The study investigates the predictive value of insertion/deletion rate in gastric cancer patients treated with nivolumab plus chemotherapy.
Understanding predictive biomarkers can guide treatment decisions and improve outcomes in gastric cancer patients receiving immunotherapy and chemotherapy.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Precision medicine in gastric cancer
- Gastric cancer
- DESTINY‑Gastric05 Phase 3 Trial of ENHERTU Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
- Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers
- Current Treatment and Recent Progress in Gastric Cancer